Kenneth Sik Kwan Chan

Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial

Chi‐Leung Chiang, K.W. Chiu, Kenneth Sik Kwan Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 119 citations

Stereotactic Body Radiotherapy, Surgical Oncology, Conversion Therapy +10

Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma

Chi‐Leung Chiang, Kenneth Sik Kwan Chan, K.W. Chiu et al. · JAMA Oncology · 2024 · 21 citations · Full text

Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma

Chi‐Leung Chiang, Francis Ann Shing Lee, Kenneth Sik Kwan Chan et al. · Liver Cancer · 2023 · 16 citations · Full text

Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial

Chi‐Leung Chiang, Tai‐Chung Lam, James Chun Bong Li et al. · The Lancet Regional Health - Western Pacific · 2023 · 11 citations · Full text

Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer

Chi‐Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li et al. · Radiotherapy and Oncology · 2024 · 11 citations